Sartorius 将来の成長

Future 基準チェック /56

Sartorius利益と収益がそれぞれ年間36.4%と9.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に20.5% 1.6%なると予測されています。

主要情報

36.4%

収益成長率

1.6%

EPS成長率

Life Sciences 収益成長	26.3%
収益成長率	9.3%
将来の株主資本利益率	20.5%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

These 4 Measures Indicate That Sartorius (ETR:SRT) Is Using Debt Reasonably Well

Jul 06

Does Sartorius (ETR:SRT) Deserve A Spot On Your Watchlist?

May 12

Sartorius Aktiengesellschaft's (ETR:SRT) CEO Will Probably Have Their Compensation Approved By Shareholders

Mar 20

Is Sartorius Aktiengesellschaft's (ETR:SRT) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Our Take On The Returns On Capital At Sartorius (ETR:SRT)

Feb 04

Here's Why We Think Sartorius (ETR:SRT) Is Well Worth Watching

Jan 13

Can Sartorius Aktiengesellschaft (ETR:SRT) Maintain Its Strong Returns?

Dec 24

What Type Of Shareholders Make Up Sartorius Aktiengesellschaft's (ETR:SRT) Share Registry?

Nov 18

業績と収益の成長予測

XTRA:SRT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,006	340	561	946	20
12/31/2025	3,624	247	452	821	21
12/31/2024	3,361	131	427	799	21
9/30/2024	3,324	77	479	924	N/A
6/30/2024	3,341	78	350	838	N/A
3/31/2024	3,312	149	144	697	N/A
12/31/2023	3,396	205	294	854	N/A
9/30/2023	3,608	358	215	821	N/A
6/30/2023	3,850	495	204	807	N/A
3/31/2023	4,053	566	182	744	N/A
12/31/2022	4,175	678	212	734	N/A
9/30/2022	4,035	534	175	690	N/A
6/30/2022	3,880	489	243	723	N/A
3/31/2022	3,683	434	414	837	N/A
12/31/2021	3,449	319	466	873	N/A
9/30/2021	3,183	372	422	770	N/A
6/30/2021	2,908	332	439	737	N/A
3/31/2021	2,617	254	350	627	N/A
12/31/2020	2,336	210	271	512	N/A
9/30/2020	2,151	181	312	503	N/A
6/30/2020	1,989	154	227	427	N/A
3/31/2020	1,901	165	171	385	N/A
12/31/2019	1,827	157	152	377	N/A
9/30/2019	1,768	171	88	337	N/A
6/30/2019	1,702	166	69	318	N/A
3/31/2019	1,637	153	63	312	N/A
12/31/2018	1,566	141	11	245	N/A
9/30/2018	1,518	138	30	245	N/A
6/30/2018	1,460	126	N/A	244	N/A
3/31/2018	1,426	115	N/A	223	N/A
12/31/2017	1,405	115	N/A	207	N/A
9/30/2017	1,376	91	N/A	185	N/A
6/30/2017	1,377	96	N/A	182	N/A
3/31/2017	1,341	105	N/A	173	N/A
12/31/2016	1,300	103	N/A	170	N/A
9/30/2016	1,250	99	N/A	145	N/A
6/30/2016	1,205	101	N/A	112	N/A
3/31/2016	1,159	96	N/A	132	N/A
12/31/2015	1,115	85	N/A	125	N/A
9/30/2015	1,076	76	N/A	160	N/A
6/30/2015	1,003	61	N/A	153	N/A
3/31/2015	946	47	N/A	107	N/A
12/31/2014	891	44	N/A	130	N/A
9/30/2014	780	43	N/A	94	N/A
6/30/2014	773	42	N/A	113	N/A
3/31/2014	780	46	N/A	112	N/A
12/31/2013	792	48	N/A	103	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SRTの予測収益成長率 (年間36.4% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: SRTの収益 ( 36.4% ) はGerman市場 ( 20.8% ) よりも速いペースで成長すると予測されています。

高成長収益: SRTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SRTの収益 ( 9.3% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: SRTの収益 ( 9.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SRTの自己資本利益率は、3年後には高くなると予測されています ( 20.5 %)

Sartorius 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023

Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023

Consensus forecasts updated

Price target decreased to €404

Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022

Price target decreased to €416

Recent updates

Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025

Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).

Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024

Sartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024

Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024

Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023

Sartorius Announces Executive Board Changes

Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023

Sartorius Announces Management Changes for Sartorius North America

Sartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023

Sartorius Aktiengesellschaft to Report First Half, 2023 Results on Jul 21, 2023

Consensus forecasts updated

First quarter 2022 earnings released

Price target decreased to €404

Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022

Price target decreased to €416

Sartorius (ETR:SRT) Has A Pretty Healthy Balance Sheet

Why The 23% Return On Capital At Sartorius (ETR:SRT) Should Have Your Attention

If You Like EPS Growth Then Check Out Sartorius (ETR:SRT) Before It's Too Late

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why Sartorius (ETR:SRT) Can Manage Its Debt Responsibly

Upcoming dividend of €1.25 per share

Investor sentiment deteriorated over the past week

We Think Sartorius' (ETR:SRT) Robust Earnings Are Conservative

Investors Interested In Sartorius Aktiengesellschaft's (ETR:SRT) Earnings

Full year 2021 earnings: Revenues exceed analyst expectations

Sartorius AG Proposes Ordinary Dividend for the Year 2021

Sartorius Aktiengesellschaft Provides Consolidated Sales Revenue Guidance for the Fiscal Year 2022 and Reaffirms Consolidated Sales Revenue for the Year 2025

If You Like EPS Growth Then Check Out Sartorius (ETR:SRT) Before It's Too Late

Investor sentiment deteriorated over the past week

Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH.

Sartorius (ETR:SRT) Is Achieving High Returns On Its Capital

Third quarter 2021 earnings released

Does Sartorius (ETR:SRT) Have A Healthy Balance Sheet?

Do Sartorius's (ETR:SRT) Earnings Warrant Your Attention?

Sartorius (ETR:SRT) Hasn't Managed To Accelerate Its Returns

Price target increased to €383

Second quarter 2021 earnings released

Sartorius Provides Earnings Guidance for the First Half Ended June 30, 2021

Sartorius Raises Group Earnings Guidance for the Full Year 2021

These 4 Measures Indicate That Sartorius (ETR:SRT) Is Using Debt Reasonably Well

Sartorius Plans to Acquire Remaining Shares of Cellgenix

Does Sartorius (ETR:SRT) Deserve A Spot On Your Watchlist?

First quarter 2021 earnings released: EPS €1.20

Sartorius AG Raises Revenue Guidance for the Year 2021

Upcoming Dividend of €0.70 Per Share

Sartorius Aktiengesellschaft's (ETR:SRT) CEO Will Probably Have Their Compensation Approved By Shareholders

Sartorius Revises Earnings Guidance for the Year 2021

Price target raised to €331

Is Sartorius Aktiengesellschaft's (ETR:SRT) Shareholder Ownership Skewed Towards Insiders?

Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)

Our Take On The Returns On Capital At Sartorius (ETR:SRT)

New 90-day high: €370

Sartorius Aktiengesellschaft to Report Fiscal Year 2020 Final Results on Feb 18, 2021

Here's Why We Think Sartorius (ETR:SRT) Is Well Worth Watching

Can Sartorius Aktiengesellschaft (ETR:SRT) Maintain Its Strong Returns?

Price target raised to €247

What Type Of Shareholders Make Up Sartorius Aktiengesellschaft's (ETR:SRT) Share Registry?

New 90-day high: €331

Sartorius Aktiengesellschaft to Report Q1, 2021 Results on Apr 21, 2021

New 90-day high: €303

Sartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million.

Sartorius Aktiengesellschaft to Report Q3, 2020 Results on Oct 20, 2020

New 90-day high - €292

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

業績と収益の成長予測

アナリストによる今後の成長予測